Clinical research of the recombinant human adenovirus-p53 combined with radiochemotherapy for advanced cervical squamocellular carcinoma / 肿瘤研究与临床

ABSTRACT

Objective To evaluate the recent clinical efficacy and safety of recombinant human adenovirus-p53 (rAd-p53) combined with radiochemotherapy in treatment for cervical squamocellular cancer (Sqc).Methods 21 patients with cervical squamous cell carcinoma were randomly divided into 2 groupsexperiment group (10 patients received treatment with rAd-p53 intratumor injection combined with radiochemotherapy) and control group (12 patients treated with radiochemotherapy alone).The recent efficacy of the two groups were compared at the end of treatment,and major drug toxicity between the two group were compared during the treatment.Results In treatment group,2 cases recieved CR,6 cases PR,2 cases SD,and the rate of total effective was 80.0 ％.In control group,3 cases recieved CR,6 cases SD,2 cases PD,and the rate of total effective was 27.3 ％.The rate of total effective in treatment group is superior to that in control group (x2 =76.00,P ＜ 0.05).The major reaction of rAd-p53 were transient fever after rAd-p53 administration.The two groups of bone marrow inhibition reaction rate with no statistical difference (x2 =119.50,P ＞ 0.05).Conclusion rAd-p53 combined with radiochemotherapy in treatment of advanced cervical squamocellular carcinoma has a synergistic effect.It is a safe,effective and convenient treatment method for rAd-p53 intratumor injection.